Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8431909 | 0.86 | ADORA3 (0.38) | ADORA3TMEM97HTR2BSIGMAR1 | |
| SCHEMBL6719057 | 0.84 | ADORA3 (0.36) | ADORA3TMEM97HTR2BSIGMAR1CYP1A2 | |
| SCHEMBL6734722 | 0.81 | ALDH1A1 (0.43) | ADORA3ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8432462 | 0.76 | ADORA3 (0.39) | ADORA3TMEM97HTR2BSIGMAR1ALDH1A1 | |
| SCHEMBL1424053 | 0.69 | PARP1 (0.52) | CYP1A2CYP3A4PARP1 | |
| SCHEMBL6723888 | 0.68 | CYP1A2 (0.37) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6666615 | 0.68 | PABPC1 (0.50) | ALDH1A1CYP3A4 | |
| SCHEMBL7219790 | 0.67 | TAAR1 (0.36) | — | |
| SCHEMBL212220 | 0.67 | ELANE (0.43) | ADORA3ALDH1A1 | |
| SCHEMBL12335334 | 0.67 | KDM4E (0.45) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790961-B2 | REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6686472-B2 | Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6608201-B2 | Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-19 | — | — | US | disclosed |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6348462-B1 | VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-19 | — | — | US | disclosed |
| US-5977366-A | 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5605899-A | VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5389640-A | Viricides, antitumor agents | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212270-A1 | Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines | IFNAR1, IRF3, IFNG | ADORA3 673/4885TMEM97 3180/4885HTR2B 1814/4885 |
| US-20020115861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines | IFNAR1, IFNG, IRF3 | ADORA3 748/4885TMEM97 2542/4885HTR2B 2195/4885 |
| US-20040122231-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | UGT1A4, QARS1, HTR4 | ADORA3 1019/4885TMEM97 3941/4885HTR2B 322/4885 |
| US-20030119861-A1 | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | IRF3, IFNAR1, IFNG | ADORA3 592/4885TMEM97 3235/4885HTR2B 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.